Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
8.98
-0.11 (-1.21%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Evolent Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Evolent Health stock have an average target of 16.64, with a low estimate of 12 and a high estimate of 35. The average target predicts an increase of 85.30% from the current stock price of 8.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evolent Health stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 6 | 6 | 6 | 6 |
| Buy | 6 | 6 | 6 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +55.90% | Apr 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +33.63% | Mar 10, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +33.63% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $17 → $16 | Buy | Reiterates | $17 → $16 | +78.17% | Feb 21, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +67.04% | Feb 21, 2025 |
Financial Forecast
Revenue This Year
2.09B
from 2.55B
Decreased by -18.15%
Revenue Next Year
2.43B
from 2.09B
Increased by 16.02%
EPS This Year
0.47
from -0.81
EPS Next Year
0.69
from 0.47
Increased by 46.08%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.2B | 2.7B | 3.2B | ||
| Avg | 2.1B | 2.4B | 2.8B | ||
| Low | 2.0B | 2.3B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -14.2% | 28.1% | 32.7% | ||
| Avg | -18.2% | 16.0% | 15.5% | ||
| Low | -22.9% | 7.7% | 2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.79 | 1.03 | 1.41 | ||
| Avg | 0.47 | 0.69 | 1.00 | ||
| Low | 0.17 | 0.42 | 0.75 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 117.4% | 103.5% | ||
| Avg | - | 46.1% | 45.2% | ||
| Low | - | -11.0% | 9.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.